Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Origin and prognostic value of circulating KRAS mutations in lung cancer patients.

Gautschi O, Huegli B, Ziegler A, Gugger M, Heighway J, Ratschiller D, Mack PC, Gumerlock PH, Kung HJ, Stahel RA, Gandara DR, Betticher DC.

Cancer Lett. 2007 Sep 8;254(2):265-73. Epub 2007 Apr 20.

PMID:
17449174
2.

Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.

Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chassé E, Ratschiller D, Weder W, Joerger M, Betticher DC, Stahel RA, Ziegler A.

J Clin Oncol. 2004 Oct 15;22(20):4157-64.

PMID:
15483026
3.

The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin.

Helbling D, Mueller BU, Timchenko NA, Hagemeijer A, Jotterand M, Meyer-Monard S, Lister A, Rowley JD, Huegli B, Fey MF, Pabst T.

Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13312-7. Epub 2004 Aug 23.

4.

Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemia.

Tschan MP, Grob TJ, Peters UR, Laurenzi VD, Huegli B, Kreuzer KA, Schmidt CA, Melino G, Fey MF, Tobler A, Cajot JF.

Biochem Biophys Res Commun. 2000 Oct 14;277(1):62-5.

PMID:
11027640

Supplemental Content

Loading ...
Support Center